Want to see JP:4597 full AI Analyst Report?
4597 Stock Chart & Stats
¥27.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥27.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥21.00 - ¥47.00
Previous CloseN/A
Volume8.51M
Average Volume (3M)41.98M
Market Cap
¥7.64B
Enterprise Value¥5.07B
Total Cash (Recent Filing)¥1.57B
Total Debt (Recent Filing)¥86.00M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.53
Shares Outstanding273,414,370
10 Day Avg. Volume52,616,870
30 Day Avg. Volume41,982,023
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.93
Price to Sales (P/S)16.06
P/FCF Ratio-8.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2
Revenue Forecast (FY)¥1.92B
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA debt-to-equity near 0.05 gives durable financial flexibility: low refinancing risk and room to fund development via equity or partnerships. Over 2-6 months this reduces insolvency risk and supports continued R&D and licensing activities without heavy interest burden.
Healthy Gross MarginA ~41% gross margin is structurally supportive for a specialty pharma firm: it implies product pricing or licensing economics that can cover variable costs. As revenue scales, this margin can translate into improved operating leverage and sustainable long-term profitability if fixed costs are controlled.
Focused Specialty Oncology ModelA concentrated in-licensing and partnering model in oncology targets unmet medical needs, enabling faster go-to-market via partners and lower early-stage R&D spend. Structurally this model can accelerate commercial adoption and preserve cash versus fully internal discovery-driven peers.
Bears Say
Persistent Cash BurnSustained negative OCF and FCF (~-1.12B TTM) is a durable constraint: it forces reliance on external financing, dilutive equity raises, or partner milestone deals. Over months this reduces strategic optionality and can pressure development timelines if fresh capital is costly or delayed.
Deep Negative ProfitabilityA net margin near -217% indicates costs far exceed current revenues, a structural earnings problem. Without material revenue growth or substantial cost restructuring, this negative profitability will persist, eroding equity returns and limiting capacity to self-fund clinical and commercial investment.
Modest/Declining Revenue & No Operating LeverageRevenue contraction (~-4.4% TTM) on a small base, combined with absent operating leverage, means fixed costs remain a drag on margins. Persisting modest sales make it hard to scale R&D and commercial efforts profitably, extending reliance on external funding over the medium term.
Solasia Pharma KK News
4597 FAQ
What was Solasia Pharma KK’s price range in the past 12 months?
Solasia Pharma KK lowest stock price was ¥21.00 and its highest was ¥47.00 in the past 12 months.
What is Solasia Pharma KK’s market cap?
Solasia Pharma KK’s market cap is ¥7.64B.
When is Solasia Pharma KK’s upcoming earnings report date?
Solasia Pharma KK’s upcoming earnings report date is Aug 13, 2026 which is in 16 days.
How were Solasia Pharma KK’s earnings last quarter?
Solasia Pharma KK released its earnings results on May 15, 2026. The company reported -¥1.14 earnings per share for the quarter, missing the consensus estimate of N/A by -¥1.14.
Is Solasia Pharma KK overvalued?
According to Wall Street analysts Solasia Pharma KK’s price is currently Overvalued.
Does Solasia Pharma KK pay dividends?
Solasia Pharma KK does not currently pay dividends.
What is Solasia Pharma KK’s EPS estimate?
Solasia Pharma KK’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solasia Pharma KK have?
Solasia Pharma KK has 273,414,370 shares outstanding.
What happened to Solasia Pharma KK’s price movement after its last earnings report?
Solasia Pharma KK reported an EPS of -¥1.14 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Solasia Pharma KK?
Currently, no hedge funds are holding shares in JP:4597
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solasia Pharma KK
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
Technical Analysis
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Modalis Therapeutics Corporation
―
Cyfuse Biomedical K.K.
―